Characterisation of Gut Microbiota in Patients Undergoing Gastrointestinal Surgery With Postoperative Delirium (GIM-POD)

Sponsor
China Medical University, China (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04316910
Collaborator
(none)
30
1
18.4
1.6

Study Details

Study Description

Brief Summary

The study is a case-controlled observational trial. Sixty patients will be divided into 2 groups depending on whether postoperative delirium or not. This study aims to characterise the gut microbiota in patients undergoing gastrointestinal surgery with postoperative delirium. The CAM-ICU (Confusion Assessment Method for Intensive Care Unit) was used for delirium assessment.

Condition or Disease Intervention/Treatment Phase
  • Drug: General anesthetic

Detailed Description

The study is a case-controlled observational trial. Sixty patients will be divided into 2 groups depending on whether postoperative delirium or not. This study aims to characterise the gut microbiota in patients undergoing gastrointestinal surgery with postoperative delirium. The CAM-ICU (Confusion Assessment Method for Intensive Care Unit) was used for delirium assessment.

General anesthesia was induced as follows: 0.3 mg kg-1 intravenous (IV) etomidate, 2 mg IV midazolam, 0.4 μg kg-1 IV sufentanil, and 0.2 mg kg-1 IV cisatracurium. Anesthesia was maintained with an end-tidal concentration of 2-3 vol% sevoflurane and 0.2-0.3 μg kg-1h-1 sufentanil to maintain the bispectral index between 40 and 60.

Study Design

Study Type:
Observational
Anticipated Enrollment :
30 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Characterisation of Gut Microbiota in Patients Undergoing Gastrointestinal Surgery With Postoperative Delirium (GIM-POD)
Anticipated Study Start Date :
Mar 19, 2022
Anticipated Primary Completion Date :
Dec 30, 2022
Anticipated Study Completion Date :
Sep 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Postoperative delirium

The CAM-ICU (Confusion Assessment Method for Intensive Care Unit) was used for delirium assessment.

Drug: General anesthetic
General anesthesia was induced as follows: 0.3 mg kg-1 intravenous (IV) etomidate, 2 mg IV midazolam, 0.4 μg kg-1 IV sufentanil, and 0.2 mg kg-1 IV cisatracurium. Anesthesia was maintained with an end-tidal concentration of 2-3 vol% sevoflurane and 0.2-0.3 μg kg-1h-1 sufentanil to maintain the bispectral index between 40 and 60.

Non-Postoperative delirium

The CAM-ICU (Confusion Assessment Method for Intensive Care Unit) was used for delirium assessment.

Drug: General anesthetic
General anesthesia was induced as follows: 0.3 mg kg-1 intravenous (IV) etomidate, 2 mg IV midazolam, 0.4 μg kg-1 IV sufentanil, and 0.2 mg kg-1 IV cisatracurium. Anesthesia was maintained with an end-tidal concentration of 2-3 vol% sevoflurane and 0.2-0.3 μg kg-1h-1 sufentanil to maintain the bispectral index between 40 and 60.

Outcome Measures

Primary Outcome Measures

  1. Characterisation of Gut Microbiota [from baseline to postoperative 72 hours]

    this study will characterise gut microbiota in 2 groups of 30 patients

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
    1. ethnic Chinese;
    1. age, 18 to 80 years old;
    1. American Society of Anaesthesiologists (ASA) physical status I or II;
    1. required Gastrointestinal Surgery
Exclusion Criteria:
  • Cognitive difficulties

  • Partial or complete gastrectomy

  • Previous esophageal surgery

  • Previous treated by radiotherapy or surgery

  • Inability to conform to the study's requirements

  • Deprivation of a right to decide by an administrative or juridical entity

  • Ongoing participation or participation in another study <1 month ago

Contacts and Locations

Locations

Site City State Country Postal Code
1 the First Hospital of China Medical University Shenyang Liaoning China 110001

Sponsors and Collaborators

  • China Medical University, China

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Wen-fei Tan, clinical professor, China Medical University, China
ClinicalTrials.gov Identifier:
NCT04316910
Other Study ID Numbers:
  • 20200319
First Posted:
Mar 20, 2020
Last Update Posted:
Nov 9, 2021
Last Verified:
Nov 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 9, 2021